A rAAV2/6 Mutant with Enhanced Targeting for Mouse Retinal Müller Cells

References

• Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008 Oct;21(4):583–93. doi:10.1128/CMR.00008-08.
   PubMed Web of Science ®Google Scholar
• Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release. 2016 Oct 28;240:287–301. doi:10.1016/j.jconrel.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Xie Y, Hicks MJ, Kaminsky SM, Moore MA, Crystal RG, Rafii A. AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. Gynecol Oncol. 2014 Nov;135(2):325–32. doi:10.1016/j.ygyno.2014.07.105.
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011 Dec 22;365(25):2357–65. doi:10.1056/NEJMoa1108046.
   PubMed Web of Science ®Google Scholar
• Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, Yu H, Vettermann C, Pierce GF, Wong WY et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017 Dec 28;377(26):2519–30. doi:10.1056/NEJMoa1708483.
   PubMed Web of Science ®Google Scholar
• Ciesielska A, Samaranch L, San Sebastian W, Dickson DW, Goldman S, Forsayeth J, Bankiewicz KS. Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial. PLoS One. 2017 Feb 6;12(2):e0169965. doi:10.1371/journal.pone.0169965.
   PubMed Web of Science ®Google Scholar
• Faustini G, Longhena F, Varanita T, Bubacco L, Pizzi M, Missale C, Benfenati F, Bjorklund A, Spano P, Bellucci A. Synapsin III deficiency hampers alpha-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson’s disease. Acta Neuropathol. 2018 Oct;136(4):621–39. doi:10.1007/s00401-018-1892-1.
   PubMed Web of Science ®Google Scholar
• Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr., Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008 May 22;358(21):2240–48. doi:10.1056/NEJMoa0802315.
   PubMed Web of Science ®Google Scholar
• Smalley E. First AAV gene therapy poised for landmark approval. Nat Biotechnol. 2017 Nov 9;35(11):998–99. doi:10.1038/nbt1117-998.
   PubMed Web of Science ®Google Scholar
• Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017 Jul 1;390(10089):50–61. doi:10.1016/S0140-6736(17)30979-0.
   PubMed Web of Science ®Google Scholar
• Constable IJ, Lai CM, Magno AL, French MA, Barone SB, Schwartz SD, Blumenkranz MS, Degli-Esposti MA, Rakoczy EP. Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a Phase 1 randomized dose escalation trial. Am J Ophthalmol. 2017 May;177:150–58. doi:10.1016/j.ajo.2017.02.018.
   PubMed Web of Science ®Google Scholar
• Ghazi NG, Abboud EB, Nowilaty SR, Alkuraya H, Alhommadi A, Cai H, Hou R, Deng WT, Boye SL, Almaghamsi A, et al. Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. Hum Genet. 2016 Mar;135(3):327–43. doi:10.1007/s00439-016-1637-y.
   PubMed Web of Science ®Google Scholar
• Beltran WA, Cideciyan AV, Boye SE, Ye GJ, Iwabe S, Dufour VL, Marinho LF, Swider M, Kosyk MS, Sha J et al. Optimization of retinal gene therapy for X-linked retinitis pigmentosa due to RPGR mutations. Mol Ther. 2017 Aug 2;25(8):1866–80. doi:10.1016/j.ymthe.2017.05.004.
   PubMed Web of Science ®Google Scholar
• Edwards TL, Jolly JK, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Black GC, Webster AR, Lotery AJ, Holder GE et al. Visual acuity after retinal gene therapy for choroideremia. N Engl J Med. 2016 May 19;374(20):1996–98. doi:10.1056/NEJMc1509501.
   PubMed Web of Science ®Google Scholar
• Komáromy AM, Alexander JJ, Rowlan JS, Garcia MM, Chiodo VA, Kaya A, Tanaka JC, Acland GM, Hauswirth WW, Aguirre GD. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet. 2010 Jul 1;19(13):2581–93. doi:10.1093/hmg/ddq136.
   PubMed Web of Science ®Google Scholar
• Byrne LC, Oztürk BE, Lee T, Fortuny C, Visel M, Dalkara D, Schaffer DV, Flannery JG. Retinoschisin gene therapy in photoreceptors, Müller glia or all retinal cells in the Rs1h-/- mouse. Gene Ther. 2014 Jun;21(6):585–92. doi:10.1038/gt.2014.31.
   PubMed Web of Science ®Google Scholar
• Devoldere J, Peynshaert K, De Smedt SC, Remaut K. Müller cells as a target for retinal therapy. Drug Discov Today. 2019 Feb 4. pii ;S1359–6446(18):30431–38. doi:10.1016/j.drudis.2019.01.023.
   Web of Science ®Google Scholar
• Biedermann B, Bringmann A, Reichenbach A. High-affinity GABA uptake in retinal glial (Müller) cells of the guinea pig: electrophysiological characterization, immunohistochemical localization, and modeling of efficiency. Glia. 2002 Sep;39(3):217–28. doi:10.1002/glia.10097.
   PubMed Web of Science ®Google Scholar
• Winkler BS, Arnold MJ, Brassell MA, Puro DG. Energy metabolism in human retinal Müller cells. Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3183–90.
   PubMed Web of Science ®Google Scholar
• Abukawa H, Tomi M, Kiyokawa J, Hori S, Kondo T, Terasaki T, Hosoya K. Modulation of retinal capillary endothelial cells by Müller glial cell-derived factors. Mol Vis. 2009;15:451–57.
   PubMed Web of Science ®Google Scholar
• Pellissier LP, Hoek RM, Vos RM, Aartsen WM, Klimczak RR, Hoyng SA, Flannery JG, Wijnholds J. Specific tools for targeting and expression in Müller glial cells. Mol Ther Methods Clin Dev. 2014 Mar 19;1:14009. doi:10.1038/mtm.2014.9.
   PubMed Web of Science ®Google Scholar
• Koerber JT, Klimczak R, Jang JH, Dalkara D, Flannery JG, Schaffer DV. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther. 2009 Dec;17(12):2088–95. doi:10.1038/mt.2009.184.
   PubMed Web of Science ®Google Scholar
• Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deleage G, Hallek M. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med. 1999 Sep 5;(9):1052–56. doi:10.1038/12491.
   PubMed Web of Science ®Google Scholar
• Buning H, Ried MU, Perabo L, Gerner FM, Huttner NA, Enssle J, Hallek M. Receptor targeting of adeno-associated virus vectors. Gene Ther. 2003 Jul;10(14):1142–51. doi:10.1038/sj.gt.3301976.
   PubMed Web of Science ®Google Scholar
• Hickey DG, Edwards TL, Barnard AR, Singh MS, de Silva SR, McClements ME, Flannery JG, Hankins MW, MacLaren RE. Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina. Gene Ther. 2017 Dec;24(12):787–800. doi:10.1038/gt.2017.85.
   PubMed Web of Science ®Google Scholar
• Klimczak RR, Koerber JT, Dalkara D, Flannery JG, Schaffer DV. A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. PLoS One. 2009 Oct 14;4(10):e7467. doi:10.1371/journal.pone.0007467.
   PubMed Web of Science ®Google Scholar
• Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol. 2006 Sep;80(18):9093–103. doi:10.1128/JVI.00895-06.
   PubMed Web of Science ®Google Scholar
• Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol. 2006 Oct;80(19):9831–36. doi:10.1128/JVI.00878-06.
   PubMed Web of Science ®Google Scholar
• Byrne LC, Khalid F, Lee T, Zin EA, Greenberg KP, Visel M, Schaffer DV, Flannery JG. AAV-mediated, optogenetic ablation of Müller Glia leads to structural and functional changes in the mouse retina. PLoS One. 2013 Sep 27;8(9):e76075. doi:10.1371/journal.pone.0076075.
   PubMed Web of Science ®Google Scholar
• Aartsen WM, van Cleef KW, Pellissier LP, Hoek RM, Vos RM, Blits B, Ehlert EM, Balaggan KS, Ali RR, Verhaagen J et al. GFAP-driven GFP expression in activated mouse Müller glial cells aligning retinal blood vessels following intravitreal injection of AAV2/6 vectors. PLoS One. 2010 Aug 24;5(8):e12387. doi:10.1371/journal.pone.0012387.
   PubMed Web of Science ®Google Scholar